Aegis Capital Reaffirms Their Buy Rating on Concert Pharma

By Jason Carr

In a report released today, Difei Yang from Aegis Capital reiterated a Buy rating on Concert Pharma (NASDAQ: CNCE), with a price target of $25. The company’s shares closed yesterday at $14.22.

According to, Yang is a 5-star analyst with an average return of 9.7% and a 50.5% success rate. Yang covers the Healthcare sector, focusing on stocks such as IntelliPharmaCeutics International, Fennec Pharmaceuticals Inc, and Spectrum Pharmaceuticals.

Concert Pharma has an analyst consensus of Moderate Buy, with a price target consensus of $28.

Based on Concert Pharma’s latest earnings report for the quarter ending March 31, the company posted quarterly revenue of $20K and GAAP net loss of $13.33 million. In comparison, last year the company earned revenue of $71K and had a GAAP net loss of $13.44 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Concert Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which discovers and develops novel small molecule drugs for renal disease, CNS disorders, inflammation and hematologic disorders. It also creates novel medicines that address commercially important needs by applying its deuterated chemical entity platform to compounds with well-characterized pharmacological activity. The company was founded by Richard H. Aldrich, Roger D. Tung and Christoph H. Westphal on April 12, 2006 and is headquartered in Lexington, MA.